Drugs / SON-1010
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05408572 | Jul 2022 → Feb 2023 | — | Sonnet BioTherapeutics | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05352750 | Apr 2022 → Jun 2026 overdue | soft tissue sarcoma | Sonnet BioTherapeutics | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05756907 | Sep 2023 → Dec 2025 | neoplasm | Sonnet BioTherapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SON-1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05408572 ↗ |
| Known as | IL12-FHAB | “SON-1010 (IL12-FHAB)” NCT05756907 ↗1“SON-1010 (IL12-FHAB)” NCT05408572 ↗ |
| Modality | Protein / enzyme biologic | “SON-1010 is a recombinant, single-chain, unmodified human rIL-12” NCT05352750 ↗ |
| Route | Subcutaneous | “SON-1010 at 50-300 ng/kg or placebo administered subcutaneously on day 1” PMID 38487528 ↗ Feb 2024 |